Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E2 production in human ovarian cancer cells

Endocrinology

Volumn 151, Issue 7, 2010, Pages 2985-2993

  Lau, Man Tat ^a   Wong, Alice S T ^b   Leung, Peter C K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FOLLITROPIN; GELATINASE A; GELATINASE B; GONADOTROPIN DERIVATIVE; LUTEINIZING HORMONE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE B; GONADOTROPIN;

ARTICLE; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; HORMONE ACTION; HUMAN; HUMAN CELL; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; TUMOR CELL; CELL MOTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; METABOLISM; OVARY TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPINS; HUMANS; LUTEINIZING HORMONE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; OVARIAN NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77954569204     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-1318     Document Type: Article

References (63)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ 2005 Cancer statistics, 2005. CA Cancer J Clin 55:10-30
2. Brekelmans CT 2003 Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol 15:63-68
3. Venn A, Watson L, Bruinsma F, Giles G, Healy D 1999 Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 354:1586-1590
4. Gnagy S, Ming EE, Devesa SS, Hartge P, Whittemore AS 2000 Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use. Epidemiology 11:102-105
5. Daly M, Obrams GI 1998 Epidemiology and risk assessment for ovarian cancer. Semin Oncol 25:255-264
6. Parrott JA, Doraiswamy V, Kim G, Mosher R, Skinner MK 2001 Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 172: 213-222
7. Zheng W, Lu JJ, Luo F, Zheng Y, Feng Y, Felix JC, Lauchlan SC, Pike MC 2000 Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 76:80-88
8. Chudecka-Glaz A, Rzepka-Górska I, Kosmowska B 2004 Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary. Arch Gynecol Obstet 270:151-156
9. Halperin R, Pansky M, Vaknin Z, Zehavi S, Bukovsky I, Schneider D 2003 Luteinizing hormone in peritoneal and ovarian cyst fluids: a predictor of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 110:207-210
10. Krämer S, Leeker M, Jäger W 1998 Gonadotropin levels in ovarian cyst fluids: a predictor of malignancy? Int J Biol Markers 13:165-168
11. Rzepka-Górska I, Chudecka-Glaz A, Kosmowska B 2004 FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary. Endocr Relat Cancer 11:315-321
12. Choi JH, Choi KC, Auersperg N, Leung PC 2006 Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 66:3912-3920
13. Schiffenbauer YS, Meir G, Maoz M, Even-Ram SC, Bar-Shavit R, Neeman M 2002 Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by α(v) -integrin. Gynecol Oncol 84:296-302
14. Bridges PJ, Komar CM, Fortune JE 2006 Gonadotropin-induced expression of messenger ribonucleic acid for cyclooxygenase-2 and production of prostaglandins E and F2α in bovine preovulatory follicles are regulated by the progesterone receptor. Endocrinology 147:4713-4722
15. Han SW, Lei ZM, Rao CV 1996 Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua. Endocrinology 137:1791-1797
16. Han SW, Lei ZM, Rao CV 1996 Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin in mucosal cells from human fallopian tubes. Endocrinology 137:2929-2937
17. Zhou XL, Lei ZM, Rao CV 1999 Treatment of human endometrial gland epithelial cells with chorionic gonadotropin/luteinizing hormone increases the expression of the cyclooxygenase-2 gene. J Clin Endocrinol Metab 84:3364-3377
18. Tsai EM, Chan TF, Chang Y, Chiang PH, Chuang CY, Long CY, Chai CY, Lee JN 2006 Leptin suppresses human chorionic gonadotropin- induced cyclooxygenase-2 expression and prostaglandin production in cultured human granulose luteal cells. J Soc Gynecol Investig 13:551-557
19. Pon YL, Wong AS 2006 Gonadotropin-induced apoptosis in human ovarian surface epithelial cells is associated with cyclooxygenase-2 up-regulation via the β-catenin/T-cell factor signaling pathway. Mol Endocrinol 20:3336-3350
20. Wang J, Luo F, Lu JJ, Chen PK, Liu P, Zheng W 2002 VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 97:163-167
21. Schiffenbauer YS, Abramovitch R, Meir G, Nevo N, Holzinger M, Itin A, Keshet E, Neeman M 1997 Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci USA 94:13203-13208
22. Smith WL, Garavito RM, DeWitt DL 1996 Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271: 33157-33160
23. Dempke W, Rie C, Grothey A, Schmoll HJ 2001 Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127:411-417
24. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE 1998 Cyclooxygenase in biology and disease. FASEB J 12:1063-1073
25. Katori M, Majima M 2000 Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 49:367-392
26. Wendum D, Masliah J, Trugnan G, Fléjou JF 2004 Cyclooxygenase- 2 and its role in colorectal cancer development. Virchows Arch 445:327-333
27. Gupta RA, Dubois RN 2001 Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1:11-21
28. Ali-Fehmi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD, Munkarah AR 2003 The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 98:1423-1429
29. Denkert C, Köbel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B, Hauptmann S 2002 Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160:893-903 (Pubitemid 34224579)
30. Landen Jr CN, Mathur SP, Richardson MS, Creasman WT 2003 Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol 188:1174-1176
31. Klimp AH, Hollema H, Kempinga C, van der Zee AG, de Vries EG, Daemen T 2001 Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 61:7305-7309
32. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, DuBois RN 2003 Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 63:906-911
33. Li S, Miner K, Fannin R, Barrett JC, Davis BJ 2004 Cyclooxygenase- 1 and 2 in normal and malignant human ovarian epithelium. Gynecol Oncol 92:622-627
34. Shi FT, Cheung AP, Leung PC 2009 Growth differentiation factor 9 enhances activin a-induced inhibin B production in human granulosa cells. Endocrinology 150:3540-3546
35. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR 1992 AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89:9267-9271
36. Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J 2001 The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 28:125-141
37. Choi JH, Choi KC, Auersperg N, Leung PC 2005 Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells. Endocr Relat Cancer 12:407-421
38. Huang Y, Lin Z, Zhuang J, Chen Y, Lin J 2008 Prognostic significance of alpha V integrin and VEGF in osteosarcoma after chemotherapy. Onkologie 31:535-540
39. Cao Z, Liu LZ, Dixon DA, Zheng JZ, Chandran B, Jiang BH 2007 Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell Signal 19:1542-1553
40. Sun H, Chen QM 2008 Inhibitors of GSK-3 prevent corticosterone from inducing COX-1 expression in cardiomyocytes. Cardiovasc Toxicol 8:93-100
41. Buchanan FG, Wang D, Bargiacchi F, DuBois RN 2003 Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278:35451-35457
42. Dannenberg AJ, Subbaramaiah K 2003 Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4:431-436
43. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S, Dubinett SM 2002 Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase- 2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 277:50828-50833
44. Sheng H, Shao J, Washington MK, DuBois RN 2001 Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276:18075-18081
45. Spinella F, Rosanò L, Di Castro V, Natali PG, Bagnato A 2004 Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 279:46700-46705
46. Stadel BV 1975 Letter: The etiology and prevention of ovarian cancer. Am J Obstet Gynecol 123:772-774
47. Choi JH, Wong AS, Huang HF, Leung PC 2007 Gonadotropins and ovarian cancer. Endocr Rev 28:440-461
48. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK 1997 Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 91:197-208
49. Matsumoto Y, Ishiko O, Deguchi M, Nakagawa E, Ogita S 2001 Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med 8:31-36
50. Richards JS, Russell DL, Robker RL, Dajee M, Alliston TN 1998 Molecular mechanisms of ovulation and luteinization. Mol Cell Endocrinol 145:47-54
51. Toth P, Li X, Lei ZM, Rao CV 1996 Expression of human chorionic gonadotropin (hCG)/luteinizing hormone receptors and regulation of the cyclooxygenase-1 gene by exogenous hCG in human fetal membranes. J Clin Endocrinol Metab 81:1283-1288
52. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M 2004 PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193-204
53. Park BK, Zeng X, Glazer RI 2001 Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res 61:7647-7653
54. Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A 2004 Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clin Cancer Res 10:4670-4679
55. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ 2000 Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14:391-396
56. Meroni SB, Riera MF, Pellizzari EH, Galardo MN, Cigorraga SB 2004 FSH activates phosphatidylinositol 3-kinase/protein kinase B signaling pathway in 20-day-old Sertoli cells independently of IGF-I. J Endocrinol 180:257-265
57. Carvalho CR, Carvalheira JB, Lima MH, Zimmerman SF, Caperuto LC, Amanso A, Gasparetti AL, Meneghetti V, Zimmerman LF, Velloso LA, Saad MJ 2003 Novel signal transduction pathway for luteinizing hormone and its interaction with insulin: activation of Janus kinase/signal transducer and activator of transcription and phosphoinositol 3-kinase/Akt pathways. Endocrinology 144:638-647
58. Alam H, Maizels ET, Park Y, Ghaey S, Feiger ZJ, Chandel NS, Hunzicker-Dunn M 2004 Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. J Biol Chem 279: 19431-19440
59. Takaoka K, Kishimoto H, Segawa E, Hashitani S, Zushi Y, Noguchi K, Sakurai K, Urade M 2006 Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 cDNA. Int J Oncol 29:1095-1101
60. Tsujii M, Kawano S, DuBois RN 1997 Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94:3336-3340
61. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR 2000 Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60:4629-4637
62. Pan MR, Chuang LY, Hung WC 2001 Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett 508:365-368
63. Symowicz J, Adley BP, Woo MM, Auersperg N, Hudson LG, Stack MS 2005 Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res 65:2234-2242